All data are based on the daily closing price as of July 18, 2025
m
Medy-Tox
086900.KQ
117.14 USD
0.48
+0.41%
Overview
Last close
117.14 usd
Market cap
770.64M usd
52 week high
159.87 usd
52 week low
77.92 usd
Target price
152.95 usd
Valuation
P/E
N/A
Forward P/E
29.8507
Price/Sales
4.5058
Price/Book Value
2.2999
Enterprise Value
778.66M usd
EV/Revenue
4.5527
EV/EBITDA
42.2706
Key financials
Revenue TTM
171.03M usd
Gross Profit TTM
103.15M usd
EBITDA TTM
33.67M usd
Earnings per Share
N/A usd
Dividend
3.16 usd
Total assets
409.29M usd
Net debt
N/A usd
About
Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hyaluronic acid filler products comprising Neuramis and Potenfill that are tissue recovering biomaterials. In addition, it provides various medical devices, such as ComfortDual for tissue coagulation by using high-frequency current; Neurajet Plus to assist injecting other pharmaceuticals; and Carewave for improving erectile dysfunction by using low-intensity shock wave generated from the electromagnetic method. It also exports its products to approximately 60 countries, including Japan, Brazil, and internationally. Medy-Tox Inc. was founded in 2000 and is headquartered in Cheongju, South Korea.